ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

Key Takeaways ALKS' alixorexton met primary goals in the phase II Vibrance-1 study for narcolepsy type 1. The 6 mg dose was the only one to meet a key secondary goal on cataplexy rates in the study. ALKS plans a global phase III trial as it eyes broader use of alixorexton in sleep disorders.Alkermes (ALKS) announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for treating patien ...